Internship

Summer Intern

Web Designer

Posted on 3/6/2024

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Compensation Overview

$22/hr

Madison, WI, USA + 2 more

More locations: Pasadena, CA, USA | San Diego, CA, USA

Category
Brand Design
Product & UX/UI Design
UI/UX & Design
Required Skills
JavaScript
UI/UX Design
Adobe Creative Suite
HTML/CSS
Requirements
  • Working on a bachelor's degree in web design or related field
  • Understand SharePoint and its structure
  • Experience with Microsoft Power Platform and PowerShell preferred
  • Proficiency in HTML, CSS, JavaScript, and related technologies
  • Knowledge of Adobe Creative Suite
  • Experience with web and mobile design
  • Understanding of UX principles
Responsibilities
  • Learn the current design framework of our main intranet page and other department pages and recommend design improvements
  • Focus on developing main intranet and People Services pages that can serve as templates for other department pages
  • Assist People Services & Culture to create Employee Recognition page
  • Assist People Services & Culture to create interactive experiences
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines that treat severe diseases by targeting and silencing the genes responsible for them using RNA interference (RNAi). This process reduces the expression of specific genes, allowing for effective treatment of conditions like cystic fibrosis and hepatitis B. Unlike its competitors, Arrowhead focuses specifically on RNAi-based therapies, addressing unmet medical needs for diseases with limited treatment options. The company's goal is to provide new therapies that improve patient outcomes and advance the field of gene silencing.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic financing with Sixth Street accelerates RNAi therapy development and commercialization.
  • Collaboration with Sarepta Therapeutics expands market reach for rare genetic disease treatments.
  • Positive Phase 2 data for plozasiran strengthens Arrowhead's position in hypertriglyceridemia treatment.

What critics are saying

  • Increased competition from companies like Alnylam Pharmaceuticals may impact market share.
  • Regulatory scrutiny could delay clinical trials and affect drug approval timelines.
  • Reliance on strategic financing may lead to increased debt obligations.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead uses RNAi to target and silence disease-causing genes effectively.
  • The company has a broad portfolio of RNA chemistries for diverse therapeutic applications.
  • Arrowhead's proprietary delivery methods ensure rapid and durable gene knockdown.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Company News

PharmaData
Mar 1st, 2025
Arrowhead Pharmaceuticals Launches FCS Patient Resources on Rare Disease Day

Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.

Business Wire
Feb 28th, 2025
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides

World Pharmaceuticals
Nov 29th, 2024
Dev4All and Pharmaseed enter commercial partnership for preclinical R&D

Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.

BioSpace
Nov 26th, 2024
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs

Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.

Endpoints News
Aug 14th, 2024
Arrowhead lays out early-stage obesity strategy, including new target on fat-storing cells

Arrowhead Pharmaceuticals unveiled a new RNAi-based obesity program on Wednesday that it believes could be "gentler" than currently available GLP-1 products...

INACTIVE